A systematic strategy to optimize ex vivo expansion medium for human hematopoietic stem cells derived from umbilical cord blood mononuclear cells.

OBJECTIVE In this study, a serum-free, stroma-free, and chemically defined medium for hematopoietic stem cell (HSC) expansion was systematically developed and optimized using factorial design and the steepest ascent method. MATERIALS AND METHODS Mononuclear cells (MNCs) were isolated from umbilical cord blood (UCB). HSCs were stimulated to proliferate ex vivo in the MNC culture system with variable serum substitutes, cytokines, and basal media according to experimental design. The expanded cells were assessed for cellular characteristics by surface antigen analysis, colony-forming cell assay (CFC assay), and long-term culture-initiating cell assay (LTC-IC assay). RESULTS The optimal compositions of serum substitutes and the cytokine cocktail for HSC expansion in the MNC culture system were BIT (4 g/L BSA, 0.71 microg/mL insulin, and 27.81 microg/mL transferrin), and CC-9 (5.53 ng/mL TPO, 2.03 ng/mL IL-3, 16 ng/mL SCF, 4.43 ng/mL FL, 2.36 ng/mL IL-6, 1.91 ng/mL G-CSF, 1.56 ng/mL GM-CSF, 2.64 ng/mL SCGF, and 0.69 ng/mL IL-11) in the Iscove's modified Dulbecco's medium. After 6-day culture, the absolute fold expansions for white blood cells, CD34+ cells, CD34+CD38- cells, CFC, and LTC-IC were 1.4-, 30.4-, 63.9-, 10.7-, 2.8-fold, respectively. CONCLUSION Using the statistic methodology to develop HSC medium, our formula had lower cytokine concentrations comparing to other literatures and commercial media, but had superior or comparable expansion ability on HSC growth.

[1]  R. Hoffman,et al.  Cocultivation of umbilical cord blood cells with endothelial cells leads to extensive amplification of competent CD34+CD38- cells. , 2000, Experimental hematology.

[2]  J. Adamson,et al.  Outcomes among 562 recipients of placental-blood transplants from unrelated donors. , 1998, The New England journal of medicine.

[3]  Alan K. Smith,et al.  Alternatives to animal sera for human bone marrow cell expansion: human serum and serum-free media. , 1998, Journal of hematotherapy.

[4]  Cindy L. Miller,et al.  Common and distinct features of cytokine effects on hematopoietic stem and progenitor cells revealed by dose–response surface analysis , 2002, Biotechnology and bioengineering.

[5]  I McNiece,et al.  Ex vivo expansion of hematopoietic progenitor cells and mature cells. , 2001, Experimental hematology.

[6]  C. Chastang,et al.  Cord Blood Banking and Transplant in Europe , 1998 .

[7]  M. Cairo,et al.  A comparison of ex vivo expanded DCs derived from cord blood and mobilized adult peripheral blood plastic-adherent mononuclear cells: decreased alloreactivity of cord blood DCs. , 2003, Cytotherapy.

[8]  G. Gilmore,et al.  Ex vivo expansion of human umbilical cord blood and peripheral blood CD34(+) hematopoietic stem cells. , 2000, Experimental hematology.

[9]  Shiaw-Min Hwang,et al.  Factorial designs combined with the steepest ascent method to optimize serum-free media for CHO cells. , 2001, Enzyme and microbial technology.

[10]  H. Mayani,et al.  In vitro proliferation, expansion, and differentiation of a CD34+ cell-enriched hematopoietic cell population from human umbilical cord blood in response to recombinant cytokines. , 2002, Archives of medical research.

[11]  J M Piret,et al.  Cytokine manipulation of primitive human hematopoietic cell self-renewal. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[12]  I-Ming Chu,et al.  Factorial designs combined with the steepest ascent method to optimize serum-free media for ex vivo expansion of human hematopoietic progenitor cells , 2003 .

[13]  H. W. Lee,et al.  Dissociation between stem cell phenotype and NOD/SCID repopulating activity in human peripheral blood CD34(+) cells after ex vivo expansion. , 2001, Experimental hematology.

[14]  Jer-Yiing Houng,et al.  Search method for the optimal medium for the production of lactase by Kluyveromyces fragilis , 1992 .

[15]  C. Shih,et al.  Long-term ex vivo maintenance and expansion of transplantable human hematopoietic stem cells. , 1999, Blood.

[16]  D. Bron,et al.  Ex vivo myeloid differentiation of cord blood CD34+ cells: comparison of four serum-free media containing bovine or human albumin. , 2003, Cytotherapy.

[17]  J. Lebkowski,et al.  Serum‐free culture of hematopoietic stem cells: A Review , 1995, Stem cells.

[18]  P. Pedrazzoli,et al.  Mitomycin C as an alternative to irradiation to inhibit the feeder layer growth in long-term culture assays. , 2000, Cytotherapy.

[19]  L. Zitvogel,et al.  Bone Marrow‐Derived Dendritic Cells Serve as Potent Adjuvants for Peptide‐Based Antitumor Vaccines , 1997, Stem cells.

[20]  M. Ogawa,et al.  In vitro expansion of hematopoietic progenitors and maintenance of stem cells: comparison between FLT3/FLK-2 ligand and KIT ligand. , 1997, Blood.

[21]  D. Sutherland,et al.  The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. , 1996, Journal of hematotherapy.

[22]  D. Sturm,et al.  The Morphology of Human Blood Cells , 2019 .

[23]  C. Chastang,et al.  Cord blood banking and transplant in Europe. Eurocord. , 1998, Bone marrow transplantation.

[24]  K. Moore,et al.  In vitro maintenance of highly purified, transplantable hematopoietic stem cells. , 1997, Blood.

[25]  D. Möbest,et al.  Serum-free ex vivo expansion of CD34(+) hematopoietic progenitor cells. , 1998, Biotechnology and bioengineering.

[26]  F. Prósper,et al.  Primitive long-term culture initiating cells (LTC-ICs) in granulocyte colony-stimulating factor mobilized peripheral blood progenitor cells have similar potential for ex vivo expansion as primitive LTC-ICs in steady state bone marrow. , 1997, Blood.

[27]  E. Papoutsakis,et al.  Serum‐free media for cultures of primitive and mature hematopoietic cells , 1994, Biotechnology and bioengineering.

[28]  Chi-Hsien Liu,et al.  Medium optimization for L-phenylalanine production by a tryptophan auxotroph of Corynebacterium glutamicum , 1994, Biotechnology Letters.

[29]  J. Dick,et al.  Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Y. Tzeng,et al.  Use of response surface methodology to optimize culture medium for production of lovastatin by Monascus ruber , 2002 .

[31]  S. Im,et al.  Adherent Cells Generated During Long‐Term Culture of Human Umbilical Cord Blood CD34+ Cells Have Characteristics of Endothelial Cells and Beneficial Effect on Cord Blood Ex Vivo Expansion , 2003, Stem cells.

[32]  I. Weissman,et al.  Isolation of a candidate human hematopoietic stem-cell population. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[33]  E. Papoutsakis,et al.  Hematopoietic cell culture therapies (Part I): Cell culture considerations. , 1996, Trends in biotechnology.

[34]  W M Miller,et al.  Hematopoietic cell culture therapies (Part II): Clinical aspects and applications. , 1996, Trends in biotechnology.

[35]  Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. , 1996, The New England journal of medicine.